NEW YORK, June 13, 2014 /PRNewswire/ -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is a biopharmaceutical company that is engaged in the discovery, development and commercialization of innovative treatments for infectious diseases. Within the anti-infective market, the company is primarily focused on developing commercially competitive, short duration combination therapies for the treatment of chronic hepatitis C virus (HCV) that are once-daily and ribavirin-free.
Hepatitis C is an infectious disease primarily affecting the liver caused by HCV, and is spread mainly by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment and transfusions. Chronic hepatitis usually occurs in 55-85% of people and can lead to permanent liver damage, which can result in the development of liver cancer, liver failure or death. The World Health Organization (WHO) estimates that approximately 130-150 million people in the world have chronic HCV, with the most affected regions being Central and East Asia and North Africa. About 3 to 4 million people are infected each year and more than 350,000 people die yearly from HCV-related diseases. In a recent report from January 2014, GBI Research estimated that the HCV global market will grow to a value of $18.6 billion by 2019 -- more than tripling its 2012 market value of $5.8 billion.
A full in-depth analyst report on ACHN that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:
Copy and paste to browser may be required.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form. A full disclaimer can be found by viewing the full analyst report.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Mike Maggi, CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.